A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.

Key facts

Study ID

NCT02045732

Run by

Pfizer

People needed

4

Starts

2014-09-01

Expected to finish

2015-10-01

Last updated by the study team

2017-01-16

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Women and men aged 18-55 yrs.
• Confirmed diagnosis of Multiple Sclerosis (MS) according to the 2010 revision of the McDonald Criteria.
• Expanded Disability Status Scale (EDSS) between 0-5, inclusive.

You may not qualify if…

• Relapse episode of MS within 2 weeks of enrollment.
• Primary progressive MS without a relapsing component.
• Intolerant or unwilling to undergo MRI scanning. Treatment with disease modifying agents up to 6 weeks prior to enrollment.

Where it is running

• Albany Advanced Imaging — Albany, New York, United States
• Fallon Wellness Pharmacy — Latham, New York, United States
• Northeast Eye Center — Latham, New York, United States
• The MS Center of Northeastern New York — Latham, New York, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Retina Vitreous Center — Edmond, Oklahoma, United States
• Lynn Health Science Institute — Oklahoma City, Oklahoma, United States
• Radiology Associates (X-ray facility only) — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.